Central precocious puberty: an Endocrine Society clinical practice guideline.
Watchful waiting is suggested for girls with early puberty between ages 7 and 8 years.
Central precocious puberty: an Endocrine Society clinical practice guideline.
Central precocious puberty (central precocious puberty), which is traditionally defined as the development of secondary sexual characteristics before age 8 years in girls and age 9 years in boys, results from the premature activation of the hypothalamic-pituitary-gonadal (hypothalamic-pituitary-gonadal) axis.
Develop evidence-based recommendations related to the diagnosis and treatment of central precocious puberty.
A multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to address 10 clinical questions related to the diagnosis and treatment of central precocious puberty.
These recommendations are largely based on evidence that girls with slowly progressive puberty attain a normal adult height without treatment.
The guideline development panel suggests against routine genetic testing for patients with central precocious puberty, although they judged that genetic testing (eg, MKRN3 sequencing) should be considered for patients with familial central precocious puberty through a shared decision-making process.
These clinical recommendations were developed to address important uncertainties in the diagnosis and treatment of children with central precocious puberty.
They are based on the best available scientific evidence regarding clinical outcomes judged to be most important to patients and families.
The guideline development panel's overarching goal was to suggest diagnostic and therapeutic strategies that will most likely provide net clinical benefits while simultaneously considering important contextual factors such as cost and feasibility.